DY268

Name: DY268
Brand: MedChemExpress
SKU: HY-110267
Rating: 5.0 (3 reviews)

Cat. No.: HY-110267 Pureza: 99.48%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

DY268 is a farnesoid X receptor (FXR) antagonist (IC₅₀=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC₅₀ value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI).

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1609564-75-1

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	Obtener un presupuesto
500 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 3 publication(s) in Google Scholar

3 Publications Citing Use of MCE DY268

2D/3D Cell Culture and Differentiation

Cell Proliferation/Viability Assay

RT-PCR

: DY268 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 May 9:115675. [Abstract]; Schematic of FXR inhibition in iHOs. Representative bright-field images of iHOs (left) and iHOs supplemented with two different FXR inhibitors (middle: DY268 (10 μm), right: ZGG). Red arrows indicate grape-like organoids.

: DY268 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 May 9:115675. [Abstract]; Counts of grape-like and total organoid formation at passage 0 (n = 5; P11025: 3, ChiPSC18: 2) based on bright-field images. Organoids with a long diameter greater than 200 mm were counted. The number of grape-like organoids was significantly lower in the FXR-inhibitor DY268 (10 μm)-supplemented groups.

: DY268 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 May 9:115675. [Abstract]; Expression levels of representative NR1H4 target genes (NR0B2, FGF19, and ABCB11) are shown on top. NR0B2 expression was significantly lower in both FXR-inhibitor DY268 (10 μm)-supplemented groups. Hepatocyte marker gene expression was also significantly lower in the FXR-inhibitor-supplemented groups (bottom).

: DY268 purchased from MedChemExpress. Usage Cited in: Microb Pathog. 2026 Jan:210:108187. [Abstract]; Effects of SBI-115 and DY268 on IPEC-J2 cells. Compounds at concentrations of 0 nM, 100 nM, 1 μM, 10 μM, and 50 μM were added to IPEC-J2 cells, which were then cultured for 48 h. Cell viability was evaluated using the CCK8 assay.

: DY268 purchased from MedChemExpress. Usage Cited in: Microb Pathog. 2026 Jan:210:108187. [Abstract]; IPEC-J2 cells were pretreated with LCA and inhibitor (DY268; 100 nM). PEDV N mRNA levels were then analyzed through qPCR.

: DY268 purchased from MedChemExpress. Usage Cited in: Microb Pathog. 2026 Jan:210:108187. [Abstract]; IPEC-J2 cells were pretreated with LCA and SBI-115 or DY268 (100 nM). PEDV N protein levels were analyzed through Western blotting.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	IC₅₀	468.5 1 Compound: 4j, DY268	Inhibition of GW4064-induced transactivation of FXR (unknown origin) expressed in HEK293T cells after 16 hrs by beta-lactamase reporter gene assay Inhibition of GW4064-induced transactivation of FXR (unknown origin) expressed in HEK293T cells after 16 hrs by beta-lactamase reporter gene assay	[PMID: 24775917]
HEK-293T	IC₅₀	468.5 1 Compound: 4j, DY268	Inhibition of GW4064-induced transactivation of FXR (unknown origin) expressed in HEK293T cells after 16 hrs by beta-lactamase reporter gene assay Inhibition of GW4064-induced transactivation of FXR (unknown origin) expressed in HEK293T cells after 16 hrs by beta-lactamase reporter gene assay	[PMID: 24775917]
HEK-293T	IC₅₀	468.5 1 Compound: 4j, DY268	Inhibition of GW4064-induced transactivation of FXR (unknown origin) expressed in HEK293T cells after 16 hrs by beta-lactamase reporter gene assay Inhibition of GW4064-induced transactivation of FXR (unknown origin) expressed in HEK293T cells after 16 hrs by beta-lactamase reporter gene assay	[PMID: 24775917]

In Vitro

DY268 (10 μM) treatment from 13 dpf to 15 dpf increased Bhmt expression in 15-dpf Tg(fabp10a:pt-β-catenin) livers compared with DMSO treatment^[2].
DY268 exhibits a>25% drop in ATP relative to vehicle-treated control at the highest concentration tested^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

560.66

Fòrmula

C₃₀H₃₂N₄O₅S

No. CAS

1609564-75-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CN(CC2=CC(OC)=CC=C2)N=C1C3=CC=C(C)C=C3)NC4=CC=C(C)C(S(=O)(N5CCOCC5)=O)=C4

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (89.18 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7836 mL	8.9181 mL	17.8361 mL
5 mM	0.3567 mL	1.7836 mL	3.5672 mL
10 mM	0.1784 mL	0.8918 mL	1.7836 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.48%

Select Batch:

Ficha de datos (275 KB) SDS (251 KB)

COA (251 KB) HNMR (203 KB) RP-HPLC (224 KB) MS (146 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Yu DD, Lin W, Forman BM, Chen T. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. [Content Brief]

[2]. Kyounghwa Jung, et al. Farnesoid X Receptor Activation Impairs Liver Progenitor Cell-Mediated Liver Regeneration via the PTEN-PI3K-AKT-mTOR Axis in Zebrafish. Hepatology. 2021 Jul;74(1):397-410. [Content Brief]

[3]. Leah M Norona, et al. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Arch Toxicol. 2020 Sep;94(9):3185-3200. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7836 mL	8.9181 mL	17.8361 mL	44.5903 mL
	5 mM	0.3567 mL	1.7836 mL	3.5672 mL	8.9181 mL
	10 mM	0.1784 mL	0.8918 mL	1.7836 mL	4.4590 mL
	15 mM	0.1189 mL	0.5945 mL	1.1891 mL	2.9727 mL
	20 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2295 mL
	25 mM	0.0713 mL	0.3567 mL	0.7134 mL	1.7836 mL
	30 mM	0.0595 mL	0.2973 mL	0.5945 mL	1.4863 mL
	40 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL
	50 mM	0.0357 mL	0.1784 mL	0.3567 mL	0.8918 mL
	60 mM	0.0297 mL	0.1486 mL	0.2973 mL	0.7432 mL
	80 mM	0.0223 mL	0.1115 mL	0.2230 mL	0.5574 mL

DY268 Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DY2681609564-75-1DY 268DY-268FXRNR1H4Inhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

DY268

Revisión del cliente

DY268 Related Antibodies

3 Publications Citing Use of MCE DY268

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

DY268 Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

DY268 Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report